Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | An update on SWOG 1318: blinatumomab followed by POMP maintenance in older patients with Ph-ALL

Harry Erba • 12 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Dasatinib
GIMEMA LAL2116 SWOG 1318

Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the SWOG 1318 study (NCT02143414), commenting on the results of the GIMEMA LAL2116 trial (NCT02744768). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Consultancy: Daiichi Sankyo, BMS

More from Harry Erba

6:32
A Phase I trial of DSP-5336, a novel menin inhibitor, in the treatment of AML
Harry Erba • 11 Dec 2023
3:03
SWOG 1318: dasatinib plus blinatumomab in the treatment of older patients with B-ALL
Harry Erba • 11 Dec 2023
5:24
Safety by treatment phase and age when treating FLT3-ITD-mutated AML with quizartinib and chemo
Harry Erba • 11 Dec 2023
3:55
Ziftomenib: a menin inhibitor for R/R NPM1-mutated AML
Harry Erba • 7 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals